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Background
The Canadian HIV Vaccine Initiative (CHVI) is a five-year
initiative between the Government of Canada and the Bill
& Melinda Gates Foundation, and it represents a signifi-
cant Canadian contribution to the Global HIV Vaccine
Enterprise that seeks to accelerate the development of safe,
effective, affordable and globally accessible HIV vaccines.
A national HIV vaccines policy agenda is currently being
developed as one measure to contribute to domestic and
international HIV vaccines policy-related efforts.
Methods
To ensure alignment with global HIV vaccines efforts, a
consultation process with international experts was
undertaken in fall 2008 – winter 2009 to seek input on
key policy issues and potential areas of focus for a Cana-
dian HIV vaccines policy agenda.
Results
The consultations identified several key policy issues that
need to be resolved domestically and globally on the pol-
icy front. These include: focussing on the science to
develop an effective vaccine; assist low- and middle-
income countries in developing regulatory systems and
processes to enable approval and implementation of clin-
ical trials, and; positioning HIV vaccines as part of a com-
prehensive prevention approach. The consultations also
identified areas of focus for the CHVI policy agenda: share
Canada's unique approach to HIV prevention; initiate and
supporting ongoing global policy dialogue; engage global
partners to raise profile of HIV/AIDS issues, and; provide
support to global approaches to address regulatory barri-
ers in HIV vaccine development and delivery.
Conclusion
The consultation process was very valuable in identifying
current global policy issues and proposed areas for inclu-
sion in a CHVI Policy Agenda. The consultations also
demonstrated the interest and support for a more formal-
ized global policy network under the leadership of the
Global HIV Vaccine Enterprise. Canada is well positioned
to develop a sound policy agenda, one that will contribute
to both domestic and global goals to advance the develop-
ment of an HIV vaccine.
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